Skip to Content
Merck
CN
  • [A sulfadiazine-tetroxoprim combination (co-tetroxazine) in the treatment of the acute exacerbation of chronic bronchitis].

[A sulfadiazine-tetroxoprim combination (co-tetroxazine) in the treatment of the acute exacerbation of chronic bronchitis].

Minerva medica (1988-07-01)
M G Gambaro, P Genoni, D Berra
ABSTRACT

After considering the bacterial flora which is most common in relapses in patients with bronchitis, 40 patients with chronic bronchitis have been treated with tetroxoprim a recently synthetized benzyl pyrimidine associated with sulfadiazine. One 350 mg tablet was administered every 12 hours for different periods, from 7 to 14 days. This study has shown how tetroxoprim has a wide antibacterial range, how it is well tolerated and extremely powerful in treating relapses of chronic infections in bronchi.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Sulfadiazine, 99.0-101.0%
Supelco
Sulfadiazine, VETRANAL®, analytical standard
Sulfadiazine for identification of impurity F, European Pharmacopoeia (EP) Reference Standard
Sulfadiazine, European Pharmacopoeia (EP) Reference Standard
Supelco
Sulfadiazine, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Sulfadiazine, United States Pharmacopeia (USP) Reference Standard